.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Glyxambi, empagliflozi...
Project Optimus is changing the landscape of oncology drug development by redefi...
Human medicines European public assessment report (EPAR): Dupixent, dupilumab, D...
Stay on top of the latest biotech news, brought to you by The Readout.
Human medicines European public assessment report (EPAR): Zubsolv, buprenorphine...
Peter Marks, M.D., Ph.D., a target for RFK Jr. and allies, last week turned in h...
Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth pl...
The Trump administration’s cuts to a global AIDS relief program threaten to upen...
EMA has issued recommendations for the influenza virus strains that vaccine manu...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
Major health news stories you need to read today.
Biologics Working Party Vaccines Quality Operational Expert Group (BV-OEG) Influ...
President Trump's threatened tariffs on Canadian drugs could lead to another $75...
EMA is exploring improvements to the development and evaluation of biosimilar me...
Closing the offices will impact efforts to improve the health of underserved pat...
Reflection paper on a tailored clinical approach in biosimilar development
Human medicines European public assessment report (EPAR): Evista, raloxifene, Da...
Layoff notices began arriving early Tuesday for thousands of employees of HHS an...
With the CSF-1R inhibitor space heating up, Merck Group has gone all-in on pimic...
SPOR and xEVMPD Stakeholder Engagement Webinars : Product Management Service (XE...
After a year of stripping back its head count and pipeline, Carisma Therapeutics...
AIRNA, a transatlantic RNA editing biotech, is preparing to launch its lead asse...
Patients are looking to pharmaceutical companies to offer healthcare services be...